Zhejiang Sunflower Great Health Co., Ltd. (SZSE: 300111)
Health Care · Pharmaceuticals · CN
CN¥3.00
-3.85% today · -22.5% 1Y
Zhejiang Sunflower Great Health Co., Ltd. (SZSE: 300111) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $574.44M and employs 303 people.
Over the last twelve months the share price has lost 22.5%, trading between 2.52 and 10.28.
Tweenvest scores Zhejiang Sunflower Great Health Co., Ltd. across four factors: quality 55/100, value 55/100, growth 0/100. Its strongest factor is quality.
300111 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $574.44M
- Revenue (TTM)
- $36.81M
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 0.48
- 52-week high
- CN¥10.28
- 52-week low
- CN¥2.52
- Avg volume (3M)
- —
- Shares outstanding
- 1.29B
- Employees
- 303
- Next earnings
- —
About Zhejiang Sunflower Great Health Co., Ltd.
Zhejiang Sunflower Great Health Co., Ltd. engages in the research, development, production, and sale of anti-infectious, cardiovascular, digestive system and other drugs in China and internationally. It offers clarithromycin API and tablets, anti-infective drugs used for nasopharyngeal infection, lower respiratory tract infection, skin and soft tissue infection, acute otitis media, Mycoplasma pneumonia, and urethritis and cervicitis; and azithromycin dispersible tablets and injections for sinusitis, acute otitis media, acute bronchitis, acute exacerbation of chronic bronchitis, streptococcus pneumoniae, pneumonia, haemophilus influenzae, mycoplasma pneumoniae, urethritis, cervicitis and skin and soft tissue infection. The company also provides roxithromycin capsules to treat pharyngitis and tonsillitis caused by Streptococcus pyogenes, sinusitis, otitis media, acute bronchitis, acute exacerbation, as well as urethritis, cervicitis, and skin and soft tissue infection. In addition, it offers lacidipine dispersible tablets for the treatment of high blood pressure; and simvastatin tablets used for hyperlipidemia, coronary heart disease combined with hypercholesterolemia, and children with heterozygous familial hypercholesterolemia. Further, the company provides omeprazole sodium for injection, a digestive system drug, used as an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; and famotidine for injection for treatment of peptic ulcer bleeding, acute gastric mucosal damage, and gastrointestinal bleeding caused by non-steroidal anti-inflammatory drugs. The company was formerly known as Zhejiang Sunflower Great Health Limited Liability Company and changed its name to Zhejiang Sunflower Great Health Co., Ltd. in December 2023. Zhejiang Sunflower Great Health Co., Ltd. was founded in 2005 and is headquartered in Shaoxing, China.
- ISIN
- CNE100000SX9
- Founded
- 2005
- Listed since
- Aug 27, 2010
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.22 | -0.96% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.